Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Rxo (RXO) Accumulated Depreciation & Amortization (2021 - 2025)

Historic Accumulated Depreciation & Amortization for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $116.0 million.

  • Rxo's Accumulated Depreciation & Amortization rose 3333.33% to $116.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $116.0 million, marking a year-over-year increase of 3333.33%. This contributed to the annual value of $116.0 million for FY2025, which is 3333.33% up from last year.
  • As of Q4 2025, Rxo's Accumulated Depreciation & Amortization stood at $116.0 million, which was up 3333.33% from $87.0 million recorded in Q4 2024.
  • Over the past 5 years, Rxo's Accumulated Depreciation & Amortization peaked at $116.0 million during Q4 2025, and registered a low of $16.0 million during Q3 2023.
  • Over the past 5 years, Rxo's median Accumulated Depreciation & Amortization value was $81.0 million (recorded in 2021), while the average stood at $67.7 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first tumbled by 2209.3% in 2023, then surged by 3333.33% in 2025.
  • Rxo's Accumulated Depreciation & Amortization (Quarter) stood at $81.0 million in 2021, then increased by 6.17% to $86.0 million in 2022, then fell by 22.09% to $67.0 million in 2023, then rose by 29.85% to $87.0 million in 2024, then surged by 33.33% to $116.0 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $116.0 million for Q4 2025, versus $87.0 million for Q4 2024 and $21.0 million for Q3 2024.